Literature DB >> 15249622

Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy.

H Koike1, K Misu, M Sugiura, M Iijima, K Mori, M Yamamoto, N Hattori, E Mukai, Y Ando, S Ikeda, G Sobue.   

Abstract

BACKGROUND: Late-onset type I familial amyloid polyneuropathy (FAP TTR Met30) cases unrelated to endemic foci in Japan show clinical features setting them apart from early-onset cases in endemic foci.
OBJECTIVE: To compare pathologic features between the early- and late-onset types.
METHODS: Pathologic findings in FAP TTR Met30 with onset before age 50 in relation to endemic foci (11 cases) were compared with those in 11 later-onset cases unrelated to endemic foci.
RESULTS: Sural nerve biopsy specimens showed predominantly small-fiber loss in early-onset cases; variable fiber size distribution, axonal sprouting, and relatively preserved unmyelinated fibers characterized late-onset cases. Autopsy cases representing both groups showed amyloid deposition throughout the length of nerves and in sympathetic and sensory ganglia, but amounts were greater in early-onset cases. Amyloid deposition and neuronal cell loss were greater in sympathetic than dorsal root ganglia in early-onset cases; the opposite was true in late-onset cases. Size assessment of remaining neurons in these ganglia suggested predominant loss of small neurons in early-onset cases but loss of neurons of all sizes in late-onset cases. Transthyretin-positive, Congo red-negative amorphous material was more conspicuous in nerves from late- than early-onset cases. In extraneural sites, amyloid was more conspicuous in thyroid and kidney from early-onset cases and in heart and hypophysis from late-onset cases. In early-onset cases, cardiac amyloid deposition was prominent in the atrium and subendocardium but was conspicuous throughout the myocardium in late-onset cases.
CONCLUSION: The pathology of early- and late-onset FAP TTR Met30 correlated well with differences in clinical findings.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15249622     DOI: 10.1212/01.wnl.0000132966.36437.12

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  45 in total

1.  Electrophysiological features of late-onset transthyretin Met30 familial amyloid polyneuropathy unrelated to endemic foci.

Authors:  Haruki Koike; Yuichi Kawagashira; Masahiro Iijima; Masahiko Yamamoto; Naoki Hattori; Fumiaki Tanaka; Masaaki Hirayama; Yukio Ando; Shu-ichi Ikeda; Gen Sobue
Journal:  J Neurol       Date:  2008-09-24       Impact factor: 4.849

2.  The spectrum of clinicopathological features in pure autonomic neuropathy.

Authors:  Haruki Koike; Rina Hashimoto; Minoru Tomita; Yuichi Kawagashira; Masahiro Iijima; Shigeru Koyano; Takayuki Momoo; Hiroyuki Yuasa; Shigehisa Mitake; Mana Higashihara; Kenichi Kaida; Daisuke Yamamoto; Shin Hisahara; Shun Shimohama; Yoshiharu Nakae; Ken Johkura; Steven Vernino; Gen Sobue
Journal:  J Neurol       Date:  2012-02-24       Impact factor: 4.849

3.  Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan.

Authors:  Taro Yamashita; Mitsuharu Ueda; Yohei Misumi; Teruaki Masuda; Toshiya Nomura; Masayoshi Tasaki; Kotaro Takamatsu; Keiko Sasada; Konen Obayashi; Hirotaka Matsui; Yukio Ando
Journal:  J Neurol       Date:  2017-11-24       Impact factor: 4.849

4.  Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR).

Authors:  Björn Pilebro; Sandra Arvidsson; Per Lindqvist; Torbjörn Sundström; Per Westermark; Gunnar Antoni; Ole Suhr; Jens Sörensen
Journal:  J Nucl Cardiol       Date:  2016-09-19       Impact factor: 5.952

5.  Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.

Authors:  A Cortese; G Vita; M Luigetti; M Russo; G Bisogni; M Sabatelli; F Manganelli; L Santoro; T Cavallaro; G M Fabrizi; A Schenone; M Grandis; C Gemelli; A Mauro; L G Pradotto; L Gentile; C Stancanelli; A Lozza; S Perlini; G Piscosquito; D Calabrese; A Mazzeo; L Obici; D Pareyson
Journal:  J Neurol       Date:  2016-03-16       Impact factor: 4.849

6.  Pathological changes long after liver transplantation in a familial amyloidotic polyneuropathy patient.

Authors:  Konen Obayashi; Mitsuharu Ueda; Toshinori Oshima; Satomi Kawahara; Yohei Misumi; Taro Yamashita; Hirofumi Jono; Masahide Yazaki; Fuyuki Kametani; Shu-ichi Ikeda; Yuki Ohya; Katsuhiro Asonuma; Yukihiro Inomata; Yukio Ando
Journal:  BMJ Case Rep       Date:  2012-08-18

7.  Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.

Authors:  Teresa Coelho; Luis F Maia; Ana Martins da Silva; Marcia Waddington Cruz; Violaine Planté-Bordeneuve; Pierre Lozeron; Ole B Suhr; Josep M Campistol; Isabel Maria Conceição; Hartmut H-J Schmidt; Pedro Trigo; Jeffery W Kelly; Richard Labaudinière; Jason Chan; Jeff Packman; Amy Wilson; Donna R Grogan
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910

8.  Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy.

Authors:  Dong Hwee Kim; Steven R Zeldenrust; Phillip A Low; Peter J Dyck
Journal:  Muscle Nerve       Date:  2009-09       Impact factor: 3.217

9.  Transthyretin amyloid goiter in a renal allograft recipient.

Authors:  Vijay K Vanguri; Vânia Nosé
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

10.  Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy.

Authors:  Maike F Dohrn; Christoph Röcken; Jan L De Bleecker; Jean-Jacques Martin; Matthias Vorgerd; Peter Y Van den Bergh; Andreas Ferbert; Katrin Hinderhofer; J Michael Schröder; Joachim Weis; Jörg B Schulz; Kristl G Claeys
Journal:  J Neurol       Date:  2013-10-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.